COMPARISON OF ANTI-HUMAN AND ANTIPORCINE FACTOR-VIII INHIBITOR LEVELS IN 63 PATIENTS WITH SEVERE HEMOPHILIA-A

被引:13
作者
FIKSSIGAUD, M
BENDELAC, L
PARQUET, A
VERROUST, F
TORCHET, MF
BERTHIER, AM
FRESSINAUD, E
GUEROIS, C
AILLAUD, MF
BONEU, B
DERLON, A
SUBTIL, E
BERTRAND, MA
BORG, JY
LAURIAN, Y
机构
[1] HAEMOPHILIA CTR, NANTES, FRANCE
[2] HAEMOPHILIA CTR, LE KREMLIN BICETRE, FRANCE
[3] HAEMOPHILIA CTR, LILLE, FRANCE
[4] HAEMOPHILIA CTR, LA QUEUE LES YVELINES, FRANCE
[5] HAEMOPHILIA CTR, NECKER, FRANCE
[6] HAEMOPHILIA CTR, RENNES, FRANCE
[7] HAEMOPHILIA CTR, ANGERS, FRANCE
[8] HAEMOPHILIA CTR, TOURS, FRANCE
[9] HAEMOPHILIA CTR, PARIS, FRANCE
[10] HAEMOPHILIA CTR, MARSEILLE, FRANCE
[11] HAEMOPHILIA CTR, TOULOUSE, FRANCE
[12] HAEMOPHILIA CTR, CAEN, FRANCE
[13] HAEMOPHILIA CTR, CLERMONT FERRAND, FRANCE
[14] HAEMOPHILIA CTR, BESANCON, FRANCE
[15] HAEMOPHILIA CTR, ROUEN, FRANCE
关键词
D O I
10.1111/j.1423-0410.1993.tb03057.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The levels of anti-human and anti-porcine factor VIII inhibitors, measured in 63 severe haemophilia A patients, lay in the ranges of <0.2-2,600 and <0.2-1,300 Bethesda units per ml (BU/ml), respectively, with a median cross-reactivity of 33%. In 4 patients, human and porcine inhibitor levels were determined using both plasma, either human or porcine, and factor VIII concentrate, either very high purity human or porcine (Hyate:C(R)). A good correlation between titres was found, whatever the source of factor VIII (plasma or concentrate). The cross-reactivity varies from 0 to over 100%, indicating that the evaluation of both human and porcine inhibitors should be mandatory before any treatment with Hyate:C. Results show that of the 46 patients with human inhibitor of more than 5 BU/ml, 21 (46%) with a low porcine inhibitor (<5 BU/ml) could benefit from Hyate:C.
引用
收藏
页码:210 / 214
页数:5
相关论文
共 15 条
[1]   THE USE OF PORCINE FACTOR-VIII CONCENTRATE (HYATE-C) IN THE TREATMENT OF PATIENTS WITH INHIBITOR ANTIBODIES TO FACTOR-VIII - A MULTICENTER US EXPERIENCE [J].
BRETTLER, DB ;
FORSBERG, AD ;
LEVINE, PH ;
ALEDORT, LM ;
HILGARTNER, MW ;
KASPER, CK ;
LUSHER, JM ;
MCMILLAN, C ;
ROBERTS, H .
ARCHIVES OF INTERNAL MEDICINE, 1989, 149 (06) :1381-1385
[2]   SEQUENTIAL ADMINISTRATION OF HUMAN AND PORCINE FACTOR-VIII FOR SURGICAL-TREATMENT OF A PAROTID TUMOR IN A PATIENT WITH A FACTOR-VIII INHIBITOR [J].
BRIET, E ;
VANDERMEER, FW ;
VANDIJKVANKEMPEN, CJM ;
SCHMIDT, PH ;
OTTEN, FWA ;
MEYER, K ;
BROEKMANS, AW .
ACTA HAEMATOLOGICA, 1985, 73 (02) :97-100
[3]   EFFICACY OF PORCINE FACTOR-VIII IN THE MANAGEMENT OF HEMOPHILIACS WITH INHIBITORS [J].
CIAVARELLA, N ;
ANTONCECCHI, S ;
RANIERI, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1984, 58 (04) :641-648
[4]  
GATTI L, 1984, THROMB HAEMOSTASIS, V51, P379
[5]  
HAY CRM, 1990, BLOOD, V76, P882
[6]  
HEDNER U, 1988, LANCET, V2, P1193
[7]  
HEDNER U, 1991, INT CONGR SER, V943, P283
[8]  
KASPER CK, 1989, PROG HEMOST THROMB, V9, P57
[9]  
KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P869
[10]  
KERNOFF PBA, 1984, BLOOD, V63, P31